Suggested Dosing
Extract
60mg PO BID-TID
Dried leaves
600 mg PO TID
Tea
1 cup PO TID; 600 mg dried leaves/150 ml water
Other Information
Topical: apply 1% cream daily
Suggested Uses
Abdominal disorders, aphrodisiac, common cold/flu, fatigue, memory enhancer, varicose veins, venous insufficiency
Topical: hypertrophic scarring, psoriasis, wound healing
Efficacy
Possibly effective for listed uses
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (25)
- amobarbital
gotu kola increases effects of amobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- azelastine
gotu kola increases effects of azelastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- brompheniramine
gotu kola increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- butabarbital
gotu kola increases effects of butabarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- butalbital
gotu kola increases effects of butalbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- carbinoxamine
gotu kola increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- chloral hydrate
gotu kola increases effects of chloral hydrate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- chlorpheniramine
gotu kola increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- cinnarizine
gotu kola increases effects of cinnarizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- clemastine
gotu kola increases effects of clemastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- cyclizine
gotu kola increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- cyproheptadine
gotu kola increases effects of cyproheptadine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- dexchlorpheniramine
gotu kola increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- dexmedetomidine
gotu kola increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- dimenhydrinate
gotu kola increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- diphenhydramine
gotu kola increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- doxylamine
gotu kola increases effects of doxylamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hydroxyzine
gotu kola increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- pentobarbital
gotu kola increases effects of pentobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- phenobarbital
gotu kola increases effects of phenobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- primidone
gotu kola increases effects of primidone by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- promethazine
gotu kola increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- secobarbital
gotu kola increases effects of secobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- triclofos
gotu kola increases effects of triclofos by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- triprolidine
gotu kola increases effects of triprolidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
Minor (23)
- acarbose
gotu kola increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- chlorpropamide
gotu kola increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- glimepiride
gotu kola increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- glipizide
gotu kola increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- glyburide
gotu kola increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin aspart
gotu kola increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin detemir
gotu kola increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin glargine
gotu kola increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin glulisine
gotu kola increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin lispro
gotu kola increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin NPH
gotu kola increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- insulin regular human
gotu kola increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- metformin
gotu kola increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- miglitol
gotu kola increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- nateglinide
gotu kola increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- pioglitazone
gotu kola increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- repaglinide
gotu kola increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- rosiglitazone
gotu kola increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- saxagliptin
gotu kola increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- sitagliptin
gotu kola increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- tolazamide
gotu kola increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- tolbutamide
gotu kola increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
- vildagliptin
gotu kola increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).
Adverse Effects
Frequency Not Defined
GI upset
Nausea
Photosensitivity
Pruritis
Topical: Allergic contact dermatitis
Burning
Large dose: Drowsiness
Hypercholesterolemia
Hyperglycemia
Hypertension
Hypertriglyceridemia
Sedation
Warnings
Contraindications
None reported
Cautions
Concurrent sedative agents, diabetes mellitus, hyperlipidemia
Pregnancy & Lactation
Pregnancy Category: avoid use
Lactation: avoid use
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
Triterpene compounds stimulate connective tissue repair, keratinization
Asiaticoside derivatives protect neurons from beta-amyloid toxicity